Literature DB >> 17046328

Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model.

Jonghan Kim1, William L Hayton, John M Robinson, Clark L Anderson.   

Abstract

The nonclassical MHC class-I molecule, FcRn, salvages both IgG and albumin from degradation. Here we introduce a mechanism-based kinetic model for human to quantify FcRn-mediated recycling of both ligands based on saturable kinetics and data from the literature using easily measurable plasma concentrations rather than unmeasurable endosomal concentrations. The FcRn-mediated fractional recycling rates of IgG and albumin were 142% and 44% of their fractional catabolic rates, respectively. Clearly, FcRn-mediated recycling is a major contributor to the high endogenous concentrations of these two important plasma proteins. While familial hypercatabolic hypoproteinemia is caused by complete FcRn deficiency, the hypercatabolic IgG deficiency of myotonic dystrophy could be explained, based on the kinetic analyses, by a normal number of FcRn with lowered affinity for IgG but normal affinity for albumin. A simulation study demonstrates that the plasma concentrations of IgG and albumin could be dynamically controlled by both FcRn-related and -unrelated parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046328      PMCID: PMC2791364          DOI: 10.1016/j.clim.2006.09.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  38 in total

Review 1.  Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura.

Authors:  Feng Jin; Joseph P Balthasar
Journal:  Hum Immunol       Date:  2005-04       Impact factor: 2.850

Review 2.  Perspective-- FcRn transports albumin: relevance to immunology and medicine.

Authors:  Clark L Anderson; Chaity Chaudhury; Jonghan Kim; C L Bronson; Manzoor A Wani; Sudhasri Mohanty
Journal:  Trends Immunol       Date:  2006-05-30       Impact factor: 16.687

3.  Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism.

Authors:  R D Wochner; G Drews; W Strober; T A Waldmann
Journal:  J Clin Invest       Date:  1966-03       Impact factor: 14.808

4.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

5.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

6.  Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.

Authors:  E Sally Ward; Jinchun Zhou; Victor Ghetie; Raimund J Ober
Journal:  Int Immunol       Date:  2003-02       Impact factor: 4.823

7.  The distribution of I131 labeled human serum albumin introduced into ascitic fluid: analysis of the kinetics of a three compartment catenary transfer system in man and speculations on possible sites of degradation.

Authors:  S A BERSON; R S YALOW
Journal:  J Clin Invest       Date:  1954-03       Impact factor: 14.808

Review 8.  Analbuminemia: report of a case and review of the literature.

Authors:  F Dammacco; A Miglietta; A D'Addabbo; A Fratello; R Moschetta; L Bonomo
Journal:  Vox Sang       Date:  1980-09       Impact factor: 2.144

9.  Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.

Authors:  V Ghetie; J G Hubbard; J K Kim; M F Tsen; Y Lee; E S Ward
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

10.  The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan.

Authors:  Chaity Chaudhury; Samina Mehnaz; John M Robinson; William L Hayton; Dennis K Pearl; Derry C Roopenian; Clark L Anderson
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

View more
  59 in total

Review 1.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 2.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

3.  A prospective, iterative, adaptive trial of carfilzomib-based desensitization.

Authors:  Simon Tremblay; James J Driscoll; Adele Rike-Shields; David A Hildeman; Rita R Alloway; Alin L Girnita; Paul A Brailey; E Steve Woodle
Journal:  Am J Transplant       Date:  2019-10-23       Impact factor: 8.086

4.  Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Authors:  Adedigbo A Fasanmade; Omoniyi J Adedokun; Joyce Ford; Danika Hernandez; Jewel Johanns; Chuanpu Hu; Hugh M Davis; Honghui Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 2.953

5.  Immunoglobulins: current understanding and future directions.

Authors:  S Jolles; S C Jordan; J S Orange; I N van Schaik
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

6.  Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.

Authors:  Deni Hardiansyah; Chee Meng Ng
Journal:  MAbs       Date:  2018-07-30       Impact factor: 5.857

7.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

8.  Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Bjørn Dalhus; Kristin Støen Gunnarsen; Jason Cameron; Algirdas Grevys; Karen Bunting; Inger Sandlie; Jan Terje Andersen
Journal:  J Biol Chem       Date:  2014-10-24       Impact factor: 5.157

9.  Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.

Authors:  Armin Sepp; Mats Bergström; Marie Davies
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

10.  Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.

Authors:  Ka Lai Yee; Huub Jan Kleijn; Thomas Kerbusch; Randolph P Matthews; Mary Beth Dorr; Kevin W Garey; Rebecca E Wrishko
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.